Kornimate/medical-research-clean huggingface dataset:
glycyrrhetinic acid combined with dexamethasone in management of newly diagnosed itp

Conditions: Immune Thrombocytopenia

Summary: the project was undertaking by qilu hospital of shandong university in china. in order to report the efficacy and safety of glycyrrhetinic acid combining with high-dose dexamethasone for the treatment of adults with newly-diagnosed primary immune thrombocytopenia (itp).

the investigators anticipate to undertaking a parallel group, single-centre, randomised controlled trial of 30 itp adult patients. one part of the participants are randomly selected to receive glycyrrhetinic acid (given compound glycyrrhizin tablets orally at a dose of 225mg per day for 1 month), combining with dexamethasone (given orally at a dose of 40 mg per day for 4 days, two-cycles with an interval of 10 days); the others are selected to receive high-dose of dexamethasone treatment plus placebo. platelet count, bleeding and other symptoms were evaluated before and after treatment. adverse events are also recorded throughout the study. in order to report the efficacy and safety of glycyrrhetinic acid combining with high-dose dexamethasone therapy for the treatment of adults with itp.

Eligibility criteria:
inclusion criteria: * meet the diagnostic criteria for immune thrombocytopenia; * untreated hospitalized patients, may be male or female, between the ages of 18\~ 80 years; * to show a platelet count \<30 \* 10\^9/l, and with bleeding manifestations; * willing and able to sign written informed consent exclusion criteria: * received chemotherapy or anticoagulants or other drugs affecting the platelet counts within 3 months before the screening visit; * received second-line itp-specific treatments (eg, cyclophosphamide, 6-mercaptopurine, vincristine, vinblastine, etc) within 3 months before the screening visit; * received high-dose steroids or ivig in the 3 weeks prior to the start of the study; * current hiv infection; * severe medical condition (lung, hepatic or renal disorder) other than chronic itp. unstable or uncontrolled disease or condition related to or impacting cardiac * female patients who are nursing or pregnant, who may be pregnant, or who contemplate pregnancy during the study period; * have a known diagnosis of other autoimmune diseases, established in the medical history and laboratory findings with positive results for the determination of antinuclear antibodies, anti-cardiolipin antibodies, lupus anticoagulant or direct coombs test; * patients who are deemed unsuitable for the study by the investigator.

Keywords: itp；glycyrrhetinic acid；dexamethasone
effect of hormone therapy on renal function

Conditions: Transgenderism; Kidney Diseases; Kidney Injury

Summary: the purpose of this study is to understand the effects of testosterone or estradiol on kidney function in transgender adolescents and young adults.


Eligibility criteria:
inclusion criteria: * identify as transgender * age 17-30 years (inclusive) * plan to start gender affirming hormone therapy (testosterone or estradiol) clinically in ≤ 1 months and remain on for at least 3 months exclusion criteria: * cognitive, psychiatric or physical impairment resulting in inability to tolerate the study procedures (e.g. intellectual disability, schizophrenia, hallucinations) * type 1 or type 2 diabetes * chronic kidney disease, or egfr \<60ml/min/1.73m2 by ckd-epi formulation * uncontrolled hypertension (resting bp ≥ 140/90 mm/hg) * allergy to shellfish, iodine or iohexol * currently taking: sulfonamides, procaine, thiazolesulfone and probenecid (renal clearance measurements of pah cannot be made accurately if individuals are on these medications) * prior gender affirming hormone therapy use * prior gonadectomy * pregnancy
phenotyping heterogeneity and regionality of the aorta

Conditions: Large Artery Stiffness; Aortic Disease; Aortic Stenosis; Aortic Aneurysm

Summary: the aorta distributes cardiac stroke volume into the whole body through its finetuned conductance function, that is propagation and modulation of flow pattern. physicomechanic properties of the aortic wall assure continuous and homogenous blood flow distribution to organs. the physicomechanic properties of the aortic wall are heterotopic: the collagen/elastin ratio doubles in the abdominal aorta as compared to the thoracic aorta. malfunction of aortic conduction due to large artery stiffening (las) leads to premature wave reflection and excess pulsatility which translate into organ damage in low-resistance beds. the regional heterogeneity of aortic physicomechanic properties and their histomorphological substrate leading to altered regional hemodynamics are not well investigated. within the pharao population, there is a spectrum of higher and lower risk patients. the aim of this cohort study is to collect prospectively and systematically clinical research data from pharao patients. this cohort study is an open-end observational study to identify master switches in aortic disease


Eligibility criteria:
1. apparently healthy volunteers inclusion criteria: • healthy volunteers exclusion criteria: * \< 18 years * active medication * cardiovascular disease * mri not possible 2. patients with aortic stenosis inclusion criteria: • patients suffering from 3rd drgree aortic stenosis exclusion criteria: * \< 18 years * mri not possible 3. patients with aortic aneurysms inclusion criteria: • patients suffering from aortic aneurysms exclusion criteria: * \< 18 years * mri not possible

Keywords: aortic disease large artery stiffness aortic stenosis aortic aneurysm
balanced salt solution vs. normal saline solution in septic shock

Conditions: Shock, Septic; Sepsis

Summary: the purpose of this study is to determine the impact of balanced salt solution versus chloride rich solution on clinical outcomes in paediatric severe sepsis or septic shock

the surviving sepsis campaign guideline recommended the isotonic crystalloids as the first choice of initial fluid resuscitation. the isotonic crystalloids are including chloride-rich solution (eg.nss) and balanced salt solution. retrospective study showed normal saline can induced hyperchloremic metabolic acidosis and acute kidney injury. however, no randomized controlled trial compare efficacy between the balanced salt solution and chloride rich solution.

Eligibility criteria:
inclusion criteria: * children younger than 18 year old who has severe sepsis or septic shock * inform consent exclusion criteria: * children who had shock from other aetiologies * end stage disease or severe congenital anomaly * refuse to inform consent

Keywords: severe sepsis, balanced salt solution, normal saline
impact of the cardiopulmonary bypass and cross-clamp time ratio on postoperative outcomes in open heart surgery: a prospective observational analysis

Conditions: CABG; Cardiac Anesthesia; Cardiac Surgery Prognosis; Bypass Complication; On-pump Valve Surgery or CABG; Anesthesia

Summary: this study aims to investigate the relationship between the ratio of cardiopulmonary bypass (cpb) time to cross-clamp (cc) time and postoperative complications in open heart surgery. while cpb time and cc duration have been linked to complications, no study has explored the specific ratio between cpb time and cc time in relation to postoperative outcomes. this prospective study seeks to fill that gap.

open heart surgery involves several distinct stages: 1) preparation for cardiopulmonary bypass (cpb), 2) the cpb phase, which includes the cross-clamp (cc) process, and 3) hemostasis and closure. during the cpb phase, the left internal mammary artery (lima) and saphenous vein are freed for coronary anastomosis, followed by arterial and venous cannulation. once cannulation is completed, cpb is initiated. a cross-clamp is placed on the aorta to stop the heart, and cardioplegia solution is administered. afterward, distal anastomoses are performed, and once completed, the cross-clamp is removed and the heart begins to beat again. the duration the cross-clamp remains in place is referred to as the cc time. in the cpb phase, proximal anastomoses are made on the aorta. after checking for any bleeding, thoracic drains are placed, and the cpb is terminated. once all controls are in place, the chest is closed, and the patient is transferred to the intensive care unit. the mortality rate for open heart surgery varies between 1% and 5%, depending on the patient's specific characteristics. postoperative complications such as bleeding revision, acute kidney injury, liver failure, respiratory failure, and heart failure are common. literature has linked these complications to vascular conditions, cpb time, and the duration of cross-clamp time. however, no studies were found that specifically compare the ratio of cpb time to cc time with postoperative complications. in this study, we aim to prospectively investigate the relationship between the ratio of cpb time to cross-clamp time and postoperative complications in patients undergoing open heart surgery.

Eligibility criteria:
inclusion criteria: * patients undergoing open heart surgery * undergo on pump surgery exclusion criteria: * patients undergoing emergency open heart surgery patients undergoing open heart surgery on a beating heart

Keywords: on-pump cabg cardiac anesthesia cross clamping cabg complications
a tube feeding study in malnourished population with diabetes

Conditions: Malnutrition; Diabetes

Summary: this is a prospective, non-interventional, observational study. malnourished subjects with diabetes, who are receiving a high calorie, high protein tube feeding with slow release carbohydrates and mufa by their health care professional (hcp) per standard of care will be enrolled into the study.


Eligibility criteria:
inclusion criteria: * voluntarily signed and dated an informed consent form, approved by an independent ethics committee, prior to any participation in the study * considered malnourished, or at risk for malnutrition * diagnosed with diabetes mellitus type 1 or 2 and treated with oral hypoglycemic medications and/or exogenous insulin * conforms to the requirements set forth on the study product label * under the care of a health care professional for malnutrition and has recently been prescribed tube feeding as a sole-source of nutrition by their health care professional * free living, residing in a nursing home or admitted to the hospital and has anticipated length of hospital stay \> 3 days and \< 12 days exclusion criteria: * severe dementia or delirium, eating disorder, history of significant neurological or psychiatric disorder, alcoholism, substance abuse or other conditions that may interfere with study product consumption or compliance with study protocol procedures * cannot safely consume the study product, or known to be allergic or intolerant to any ingredient found in the study product * renal or liver failure * participates in another study that has not been approved as a concomitant study by an
sema-cardiodiab hungary: a research study to understand the effects of oral semaglutide on blood sugar levels, weight, and cardiovascular risk in people with type 2 diabetes patients in hungary

Conditions: Type 2 Diabetes

Summary: participant will get oral semaglutde as prescribed by the study doctor. the study will last for about 26 ± 4 weeks (5 to 7 months). participant will be asked to complete a questionnaire about how they take oral semaglutide tablets during normal scheduled visit with doctor. participant will also be asked questions about health and their diabetes treatment and lab tests as part of normal doctor's appointment.


Eligibility criteria:
inclusion criteria: * signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). * the decision to initiate treatment with commercially available oral semaglutide has been made by the patient/lar and the treating physician based on local label before and independently from the decision to include the patient in this study. * male or female, adults above or equal to 18 years of age at the time of signing informed consent. * diagnosed with type 2 diabetes mellitus. * patient on metformin (met) with or without modern oral antidiabetic (moad, that is dipeptidyl peptidase-4 inhibitor \[dpp4i\] or/and sodium-glucose cotransporter-2 inhibitor \[sglt2i\]) with or without insulin therapy. * available hba1c value \> 7.0% within 90 days prior to the 'informed consent and treatment initiation visit' (v1) or hba1c measurement taken in relation with the 'informed consent and treatment initiation visit' (v1) if in line with local clinical practice. exclusion criteria: * previous participation in this study (defined as having given informed consent in this study earlier). * treatment with any investigational drug within 30 days prior to enrolment into the study. * mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation. * glucagon like peptide -1 receptor agonist (glp1-ra) treatment within 90 days prior to the treatment initiation visit (v1). * patients diagnosed with type 1 diabetes mellitus. * female who is known to be pregnant, undergoing fertility treatment, breastfeeding or intends to become pregnant during the study duration.
effects of upper extremity manual lymphatic drainage on symptom severity, hand functions, electrophysiological and ultrasonographic measurements in carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome

Summary: this study is aimed to investigate the effects of upper extremity manual lymphatic drainage, which is applied to remove edema from the carpal tunnel region in addition to conventional exercise therapy in carpal tunnel syndrome patients on findings of clinical, ultrasonographic, and electrophysiological.

thirtyfour volunteer participants between aged 40 and 60 years, who met the inclusion criteria, will be included in the study. participants will be randomly divided into two groups experimental and control groups. while the control group will receive only conventional exercises, the experimental group will receive both conventional exercises and upper extremity manual lymphatic drainage. a total of 3 measurements will be made before the treatment, after the treatment and 1 month after the end of the treatment. symptom severity will be evaluated via boston carpal tunnel syndrome questionnaire, grip strength via hand dynamometer, pressure pain threshold via digital algometer device, cross-sectional area of the median nerve via ultrasound, and median nerve conduction velocity via superficial emg device.

Eligibility criteria:
inclusion criteria: * people aged between 40-60 years * having been diagnosed with carpal tunnel syndrome (cts) at least 6 months ago or having symptoms related to carpal tunnel syndrome for at least 6 months * having mild (median nerve sensory conduction velocity below 40 m/sec) and moderate (median nerve sensory conduction velocity below 40 m/sec and median motor distal latency 4 ms and above) cts according to electrophysiological findings * not having received medical treatment and/or physiotherapy for cts in the last 6 months exclusion criteria: * having cervical radiculopathy * having thoracic outlet syndrome * presence of systemic disease that may lead to cts, such as diabetes or thyroid disease * pregnancy * presence of anemia * having a history of cts surgery * presence of radial or ulnar nerve sensory-motor lesions accompanying the present condition * presence of lymphedema * having severe (sensory nerve action potential cannot be obtained) and severe (sensory nerve action potential cannot be obtained, but combined muscle action potential is not present) cts according to electrophysiological findings

Keywords: carpal tunnel syndrome manual lymphatic drainage surface electromyography
an extension study to evaluate the long-term safety of lampalizumab in participants with geographic atrophy

Conditions: Geographic Atrophy

Summary: this is a multicenter, open-label extension study of safety and tolerability of lampalizumab administered by intravitreal (itv) injection to participants with geographic atrophy (ga) who have completed the 18-month treatment in study cfd4870g (gx01456) (nct01229215) or 24-week treatment in study gx29455 (nct02288559).


Eligibility criteria:
inclusion criteria: * for cfd4870g participants: previous enrollment and completion (month 18 visit) of study cfd4870g without early treatment discontinuation (lampalizumab or sham) * for gx29455 participants: previous enrollment and completion (week 24 visit) of study gx29455 without early treatment discontinuation (lampalizumab or sham) * sufficiently clear ocular media, adequate pupillary dilation, and fixation to permit quality fundus imaging exclusion criteria: * early treatment and/or study discontinuation prior to completion of study cfd4870g (gx01456) and gx29455 * vitrectomy surgery, submacular surgery, or other surgical intervention for age-related macular degeneration (amd) in the study eye * subfoveal focal laser photocoagulation in the study eye * treatment with visodyne, external-beam radiation therapy, or transpupillary thermotherapy in the study eye * intravitreally (itv) drug delivery (e.g., itv corticosteroid injection, anti-angiogenic drugs, anticomplement drugs, or device implantation) in the study eye. lampalizumab in study eye and ranibizumab in either eye are permitted * any concurrent ocular or intraocular condition in the study eye that contraindicates the use of an investigational drug or may affect interpretation of the study results or may render the participant at high risk for treatment complications
induction of labor versus expectant management of large for gestational age/macrosomic babies at term. a multi-center trial

Conditions: Macrosomia; Induction of Labor; Expectant Management; Shoulder Dystocia

Summary: the equipoise whether to induce pregnant women with suspected large for gestational babies or suspected macrosomia babies at term pregnancy is not solved yet. only 2 relatively small studies were conducted to answer this clinically important question. the investigators will conduct a randomized controlled, multi-center study large enough to confirm or refute our assumption that induction of labor at term reduces the shoulder dystocia prevalence significantly compared to expectant management.

background: macrosomia at term is associated with increased maternal and neonatal morbidity, including a higher rate of shoulder dystocia and cesarean section (cs). induction of labor (iol) has been suggested as a means to prevent further fetal weight gain and therefore to reduce possible neonatal and maternal complications which are related to fetal weight. working hypothesis and aims: the aims of this study are: 1) to determine whether or not iol improves maternal and neonatal outcome in large for gestational age babies, 2) to determine maternal satisfaction from the labor and delivery process in both study groups. our working hypothesis is that iol will reduce the shoulder dystocia and cs rate of lga\\macrosomic babies at term. methods: patient from 38+0 - 40+3 gestational weeks estimated fetal weight 3800 - 4500 gr will prospectively and randomly allocated into two groups: iol (group i) and expectant management (group ii). women with diabetes, a previous cesarean delivery, or other contraindications for vaginal delivery or candidates for iol for other reasons will be excluded from the study. outcome variables will include shoulder dystocia, brachial plexus injury, bone fractures, cephalhematoma, intraventricular hemorrhage, cesarean delivery and other neonatal and maternal variables. expected results: iol will reduce the shoulder dystocia and cs rate of lga\\macrosomic babies at term. importance: this randomized, prospective multicenter study addresses a prevalent clinical question which does not have an accurate answer in the medical literature. current guidelines rely on small numbered patients, and are over 15 years old studies. probable implications to medicine: this study will establish the right management for lag\\macrosomic babies at term, iol or expectant management for spontaneous labor.

Eligibility criteria:
inclusion criteria: * singleton, * live fetus, * vx presentation, * efw 3800-4500 grams, * eligible for vaginal delivery, * signed the informed consent. exclusion criteria: * pr. cs, * diabetes, * fetal major malformations, * maternal/fetal illness or condition requiring iol.

Keywords: macrosomia induction of labor expectant management shoulder dystocia
leave or laparoscopic appendectomy with normal findings - a regional cohort study

Conditions: Appendicitis Acute

Summary: based on a regional cohort, this study we will try to demonstrate the superiority of routine laparoscopic appendectomy vs. leaving an intraoperative assessed normal appendix in situ in cases of normal findings at diagnostic laparoscopy. if routine laparoscopic appendectomy is not superior, we will recommend leaving the "normal" appendix in situ.

the study is a retrospective cohort study with a superiority design. it will be carried out at the surgical departments of the four public university hospitals providing emergency surgical service to the entire population of 1,8 million in the capital region of denmark. on march 17, 2017, a new electronic health record (ehr) had been implemented at three of the hospital, while it was implemented at copenhagen university hospital - bispebjerg on may 20, 2017. these dates mark the start of the inclusion period for each hospital, while the inclusion period ended april 1, 2021 for all four hospitals. the "snap boards" covering the relevant operation rooms at the four hospitals will be systematically review. for all cases, where diagnostic laparoscopy was performed on suspicion of acute appendicitis, the ehr will be reviewed.

Eligibility criteria:
inclusion criteria: * diagnostic laparoscopy with normal intraoperative findings (including mesenteric adenitis * laparoscopic appendectomy and a histopathological normal appendix and otherwise normal intraoperative findings (including mesenteric adenitis) exclusion criteria: * diagnostic laparoscopy with abnormal intraoperative findings. * laparoscopic appendectomy and a histopathological non-normal appendix. * laparoscopic appendectomy and a histopathological normal appendix and abnormal intraoperative findings.

Keywords: laparoscopic appendectomy normal findings